Evidence map›Paper›PMID 31758811›Full record

ArticleHepatology (Baltimore, Md.)2020

Impact of Alcohol Use Disorder Treatment on Clinical Outcomes Among Patients With Cirrhosis.

Shari Rogal, Ada Youk, Hongwei Zhang, Walid F Gellad, Michael J Fine, Chester B Good, Maggie Chartier, Andrea DiMartini, Timothy Morgan, Ramon Bataller and 1 more

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in Hepatology (Baltimore, Md.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06471686 (Safety of Acamprosate in Treating Alcohol Use Disorder in the Post Liver Transplant Populations), which is not on this map. Cited by 106 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
106citing papers in PubMed, 5 pooled it
10.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06471686 phase2completednot on this mapstarted 2021, after this paper: background citation

Safety of Acamprosate in Treating Alcohol Use Disorder in the Post Liver Transplant Populations

TypeinterventionalSponsorUniversity of Southern CaliforniaRan2021 to 2023Enrolled30ConditionsAlcohol Use Disorder, Liver Transplant, ComplicationsArmsAcamprosate
3 · Its place in the literature

Who cites it

106 citing papers in PubMed, 5 syntheses or guidelines pooled it, 208 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Early liver transplantation in alcohol-associated liver disease-Evolution of practice, patient selection, management, and outcomes.Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society · 2026
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

46 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Shari RogalCenter for Health Equity Research and Promotion, VA Pittsburgh Healthcare System, Pittsburgh, PA.ORCID 0000-0001-8184-1546
Ada YoukCenter for Health Equity Research and Promotion, VA Pittsburgh Healthcare System, Pittsburgh, PA.
Hongwei ZhangCenter for Health Equity Research and Promotion, VA Pittsburgh Healthcare System, Pittsburgh, PA.
Walid F GelladCenter for Health Equity Research and Promotion, VA Pittsburgh Healthcare System, Pittsburgh, PA.
Michael J FineCenter for Health Equity Research and Promotion, VA Pittsburgh Healthcare System, Pittsburgh, PA.
Chester B GoodCenter for Health Equity Research and Promotion, VA Pittsburgh Healthcare System, Pittsburgh, PA.
Maggie ChartierHIV, Hepatitis, and Related Conditions Programs, Office of Specialty Care Services, Veterans Health Administration, Washington, DC.
Andrea DiMartiniDepartment of Surgery, School of Medicine, University of Pittsburgh, Pittsburgh, PA.
Timothy MorganGastroenterology Section, VA Long Beach Healthcare System, Long Beach, CA.ORCID 0000-0003-1328-0307
Ramon BatallerDivision of Gastroenterology, Hepatology, and Nutrition, School of Medicine, University of Pittsburgh, Pittsburgh, PA.ORCID 0000-0002-1119-7799
Kevin L KraemerCenter for Health Equity Research and Promotion, VA Pittsburgh Healthcare System, Pittsburgh, PA.
University of Pittsburgh · USUniversity of California, Irvine · USVA Pittsburgh Healthcare System · USVeterans Health Administration · US

Funding

The University of Pittsburgh's Comparative Effectiveness Research Scholars PrograK12HS019461 · AHRQ · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KAPOOR, WISHWA N · 2010 to 2010
$1.9M
AHRQ HHS K12 HS019461VA VISN 4 Competitive Pilot Project Fund Grant
6 · The paper itself

Abstract

BACKGROUND AND

aimsDespite the significant medical and economic consequences of coexisting alcohol use disorder (AUD) in patients with cirrhosis, little is known about AUD treatment patterns and their impact on clinical outcomes in this population. We aimed to characterize the use of and outcomes associated with AUD treatment in patients with cirrhosis. APPROACH AND

resultsThis retrospective cohort study included Veterans with cirrhosis who received Veterans Health Administration care and had an index diagnosis of AUD between 2011 and 2015. We assessed the baseline factors associated with AUD treatment (pharmacotherapy or behavioral therapy) and clinical outcomes for 180 days following the first AUD diagnosis code within the study time frame. Among 93,612 Veterans with cirrhosis, we identified 35,682 with AUD, after excluding 2,671 who had prior diagnoses of AUD and recent treatment. Over 180 days following the index diagnosis of AUD, 5,088 (14%) received AUD treatment, including 4,461 (12%) who received behavioral therapy alone, 159 (0.4%) who received pharmacotherapy alone, and 468 (1%) who received both behavioral therapy and pharmacotherapy. In adjusted analyses, behavioral and/or pharmacotherapy-based AUD treatment was associated with a significant reduction in incident hepatic decompensation (6.5% vs. 11.6%, adjusted odds ratio [AOR], 0.63; 95% confidence interval [CI], 0.52, 0.76), a nonsignificant decrease in short-term all-cause mortality (2.6% vs. 3.9%, AOR, 0.79; 95% CI, 0.57, 1.08), and a significant decrease in long-term all-cause mortality (51% vs. 58%, AOR, 0.87; 95% CI, 0.80, 0.96).

conclusionsMost Veterans with cirrhosis and coexisting AUD did not receive behavioral therapy or pharmacotherapy treatment for AUD over a 6-month follow-up. The reductions in hepatic decompensation and mortality suggest that future studies should focus on delivering evidence-based AUD treatments to patients with coexisting AUD and cirrhosis.

Indexed as

AlcoholismCognitive Behavioral TherapyDrug TherapyLiver CirrhosisLiver Diseases, AlcoholicLiver FailureAlcohol AbstinenceFemaleHumansMaleMiddle AgedMortalityOutcome Assessment, Health CareRetrospective StudiesUnited StatesUnited States Department of Veterans Affairs

Identifiers

PMID31758811
PMCPMC8032461
OpenAlexW2991209261

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.